Search

for
Search:

Glossary deuruxolitinib

medication inhibiting enzymes to treat autoimmune hair loss

Deuruxolitinib is a medication that inhibits Janus kinase (JAK) enzymes, which are involved in the inflammatory process. It is being studied for its potential to treat conditions like alopecia areata, an autoimmune disorder that causes hair loss, by reducing the immune system's attack on hair follicles.

Research

5 / 166 results

research Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)

63 citations , July 2024 in “Journal of the American Academy of Dermatology”

This study found that the oral JAK1/JAK2 inhibitor deuruxolitinib effectively promoted hair regrowth and patient satisfaction in adults with alopecia areata over 24 weeks.

research 62823 Optimization of deuruxolitinib dosing in adult patients with alopecia areata: Results from a randomized, parallel-group, multicenter, Phase 2 trial

4 citations , September 2025 in “Journal of the American Academy of Dermatology”

The trial helped find the best dose of deuruxolitinib for treating alopecia areata.

research FDA approval of Deuruxolitinib: A New Treatment Option for Severe Alopecia Areata

3 citations , November 2024 in “Clinical Research”

This article discusses the immune mechanisms involved in alopecia areata, focusing on T-cell activity and cytokine-driven JAK signaling, but reports no new clinical results.

research Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial

2 citations , November 2025 in “Journal of the American Academy of Dermatology”

In this randomized, placebo-controlled trial, adults with severe chronic alopecia areata who received deuruxolitinib showed significant hair regrowth compared to placebo over 24 weeks, and the treatment was generally well-tolerated, though long-term effects remain unexamined.

research Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients

2 citations , October 2025 in “Frontiers in Medicine”

This study found that deuruxolitinib may effectively improve hair regrowth and patient satisfaction in moderate to severe alopecia areata, but careful monitoring is needed due to manageable side effects and concerns about long-term safety.

View more "deuruxolitinib" in research →

Learn

— no results

Try a deeper search in learn →

Community Join

— no results

Try a deeper search in community →

Experts

— no results

Try a deeper search in experts →

Clinics

— no results

Try a deeper search in clinics →